CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-19 | VAN BEEK JEROEN B Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2020-12-01 | Miller Edward General Counsel | Gift | −41,514 | 166,051 | ||
| 2020-12-01 | Miller Edward General Counsel | Gift | +41,514 | 198,811 | ||
| 2020-11-30 | Leen Ann M. Chief Scientific Officer | Gift | −60,394 | 0 | ||
| 2020-11-30 | Leen Ann M. Chief Scientific Officer | Gift | +60,394 | 60,394 | ||
| 2020-08-03 | Vera Juan Director | Conversion | +2,436,773 | 2,466,970 | ||
| 2020-08-03 | Vera Juan Director | Conversion · Series A-3 Convertible Preferred Stock | −3,631,293 | 0 | ||
| 2020-08-03 | Wilson John Robert Director | Conversion | +3,184,758 | 3,214,955 | ||
| 2020-08-03 | Wilson John Robert Director | Conversion | +2,347,999 | 5,562,954 | ||
| 2020-08-03 | Wilson John Robert Director | Conversion · Series A-3 Convertible Preferred Stock | −4,745,943 | 0 | ||
| 2020-08-03 | Wilson John Robert Director | Conversion · Series A-3 Convertible Preferred Stock | −3,499,001 | 0 | ||
| 2020-08-03 | Bornstein Jeffrey S Director | Conversion | +20,583 | 20,583 | ||
| 2020-08-03 | Bornstein Jeffrey S Director | Conversion · Series B Preferred Convertible Stock | −30,674 | 0 | ||
| 2020-08-03 | Miller Edward General Counsel | Conversion | +32,759 | 32,759 | ||
| 2020-08-03 | Miller Edward General Counsel | Conversion · Series B Convertible Preferred Stock | −48,819 | 0 | ||
| 2020-08-03 | Leen Ann M. Chief Scientific Officer | Conversion | +2,436,773 | 2,436,773 | ||
| 2020-08-03 | Leen Ann M. Chief Scientific Officer | Conversion · Series A-3 Convertible Preferred Stock | −3,631,293 | 0 | ||
| 2020-08-03 | Jovan-Embiricos Morana Director | Conversion | +13,420,970 | 13,420,970 | ||
| 2020-08-03 | Jovan-Embiricos Morana Director | Conversion | +247,011 | 247,011 | ||
| 2020-08-03 | Jovan-Embiricos Morana Director | Conversion | +1,399,732 | 1,399,732 |
Page 26 of 27 · 527 trades